|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Com-parison of idarubicin+ara-C,fludarabine+ara-C,andtopotecan+ara-C-based regimens in treatment ofnewly diagnosed acute myeloid leukemia,refractory a-nemia with excess blasts in transformation,or refrac-tory anemia with excess blasts显示文摘 | ESTEY E H THALL P F CORTES J E | 2001 | Blood2001，98，： | 1 |
| 2 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia显示文摘 | ANDERSSON B S THALL P F MADDEN T | 2002 | Biol Blood Marrow Transplantation2002，8，9： | 1 |
| 3 | Some covariance models for longitudinal data with overdispersion显示文摘 | Thall P F Vail SC | 1990 | Biometrics1990，46，4： | 1 |
| 4 | Mixed Poisson Likelihood Regression Models for Longitudinal Interval Count Data显示文摘 | Thall P F | 1988 | Biometrics1988，44，： | 1 |
| 5 | Caspase-2 and Caspase-3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia显示文摘 | Faderl S Thall P F Kantarjian H M | 1999 | Clin Cancer Res1999，5，12： | 1 |
| 6 | Effect of Time to Complete Remission on Subsequent Survival and Disease Free Survival Time in AML,RA EB-t,RAEB显示文摘 | Estey E H Shen Y Thall P F | 2000 | Blood2000，95，1： | 1 |
| 7 | Mainte nance therapy with low-dose zazcitidine after alloge- neic hematopoietic stem cell transplantation for recur- rent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study 显示文摘 | DE LIMA M GIRALT S THALL P F | 2010 | Cancer2010，116，： | 1 |
| 8 | Comparison of idarubicin +ara-C-,fludarabine +ara-C-,and topotecan +ara-C-,based regimens in treat ment of newly diagnosed acute myeloid leukemia,refractory anemia with excess blasts in transformation,or refractory anemia with excess blasts显示文摘 | Estey E H Thall P F Cortes J E | 2001 | Blood2001，98，： | 1 |
| 9 | Effect of time to complete remission on subsequent survival and disease free survival time in AML, RAEB - T, RAEB显示文摘 | ESTEY E H SHEN Y THALL P F | 2000 | Blood2000，95，1： | 1 |
| 10 | Comparison of idarubicin + ara - C - , fludarabine + ara - C - , and topotecan + ara- C- based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transfor- mation, or refractory anemia with excess blasts显示文摘 | ESTEY E H THALL P F CORTES J E | 2001 | Blood2001，98，13： | 1 |
| 11 | Some covariance models for longitudinal count data with overdispersion 显示文摘 | Thall P F Vail S C | 1990 | Biometrics1990，46，： | 1 |
| 12 | Effect of time to complete remission on subsequent survival and disease-free survival time in AML,RAEB-t,and RAEB显示文摘 | Estey E H Shen Y Thall P F | | 0，，01： | 1 |
| 13 | Treatment of newly diagnosed acute promyelocytic leukemia without cyt-arabine显示文摘 | ESTEY E THALL P F PIERCE S | 1997 | J Clin Oncol1997，15，2： | 1 |
| 14 | Comparison of idarubicin + ara C-,fludarabine +ara-C-,and topotecan+ara C-based regimens in treatment of newly diagnosed acute myeloid leukemia,refractory anemia with excess blasts in transformation,or refractory anemia with excess blasts显示文摘 | ESTEY E H THALL P F CORTES J E | 2001 | Blood2001，98，13： | 1 |
| 15 | Comparison of idarubicin + ara-C,fludarabine + ara-C,and topotecan + araC based regimans in treatment of newly diagnesed acute myeloid leukemia,refractory anemia with excess blasts in transformation,or refractory anemia with excess blasts显示文摘 | Estey E H Thall P F Cortes JE | 2001 | Blood2001，98，13： | 1 |
| 16 | Vorinostat Combined with High-Dose Gemcitabine,Busulfan,and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas显示文摘 | Nieto Y Valdez B C Thall P F | 2015 | Biology of Blood and Marrow Transplantation2015，21，11： | 1 |
| 17 | Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission显示文摘 | Faderl S Thall P F Kantarjian H M | 2002 | Br J Haematol2002，117，4： | 1 |
| 18 | Some covariance models for lon- gitudinal count data with overdispersion显示文摘 | THALL P F VAIL S C | 1990 | Biometrics1990，46，3： | 1 |
| 19 | Effect of time to complete remission on subsequent survival and disease - free survival time in AML, RAEB-t, and RAEB 显示文摘 | ESTEY E H SHEN Y THALL P F | 2000 | Blood2000，95，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员